About Lung Cancer: A Patient Overview of Types, Stages, and Treatment
Share
Lung cancer is the leading cause of cancer death worldwide, but it is also one of the most actively researched diseases in oncology. New targeted therapies, immunotherapies, and screening programs have changed outcomes meaningfully over the past decade. This guide gives patients a practical overview of lung cancer including the main types, how it is staged, how it is treated, and how to access expert care in China.
Understanding Lung Cancer
Lung cancer starts when cells in the lung grow uncontrollably and form a tumor. Most lung cancers begin in the lining of the bronchi or in smaller air passages. Risk factors include tobacco smoking, secondhand smoke, radon, asbestos, air pollution, occupational exposures, and certain genetic factors. About 10 to 20 percent of lung cancers occur in people who have never smoked, and these cases are often driven by specific genetic mutations.
Lung cancer is broadly divided into two categories. Non small cell lung cancer accounts for roughly 85 percent of cases and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Small cell lung cancer accounts for the other 15 percent and behaves more aggressively, often spreading early.
Early lung cancer rarely causes symptoms. By the time it produces a persistent cough, hemoptysis, breathlessness, chest pain, or weight loss, it is often already locally advanced. This is why low dose CT screening for high risk smokers has become a priority.
Who Needs Evaluation
A person should seek prompt evaluation if they have:
- An unexplained cough lasting more than 3 weeks
- Blood in the sputum
- Recurrent chest infections
- Unexplained weight loss or fatigue
- New onset shortness of breath
- A lung nodule found on a CT or chest X-ray performed for another reason
- A strong smoking history that meets screening criteria
For asymptomatic high risk adults, annual low dose CT is recommended for those aged 50 to 80 with at least a 20 pack year smoking history. This screening reduces lung cancer mortality by around 20 percent in eligible populations.
How It's Performed
A full lung cancer workup at a high volume center typically includes:
- High resolution CT of the chest with intravenous contrast
- PET-CT for staging
- Brain MRI to rule out brain metastases in most patients
- Pulmonary function tests
- Bronchoscopy or CT guided biopsy of the tumor
- Endobronchial ultrasound with mediastinal lymph node sampling
- Full molecular and immunohistochemical testing including EGFR, ALK, ROS1, KRAS G12C, BRAF, MET, RET, HER2, NTRK, and PD-L1
- Multidisciplinary review by thoracic surgery, medical oncology, radiation oncology, and pulmonology
The complete workup usually takes one to two weeks. Treatment depends critically on the stage and molecular profile, so a rushed workup is rarely in the patient's interest.
Cost and Access
A full diagnostic workup costs:
- United States cash price: $20,000 to $40,000
- United Kingdom private: GBP 10,000 to 20,000
- Mainland China top cancer centers: RMB 30,000 to 60,000, roughly $4,300 to $8,600
Treatment costs vary by stage and modality. Surgery for stage 1 or 2 disease, concurrent chemoradiation for stage 3, and immunotherapy combinations or targeted therapy for stage 4 are all standard. Targeted therapy with EGFR or ALK inhibitors costs a fraction in mainland China compared to the United States, because many of these drugs are domestically produced and reimbursed.
What Results Mean
Lung cancer is staged using the TNM system. T describes tumor size and local extent, N describes lymph node involvement, and M describes distant metastases. The combined stage ranges from stage 1 through stage 4.
Five year survival varies dramatically by stage at diagnosis:
- Stage 1: 60 to 80 percent for non small cell lung cancer
- Stage 2: 40 to 55 percent
- Stage 3: 13 to 36 percent
- Stage 4: 6 to 10 percent overall, much higher in patients with actionable driver mutations on targeted therapy
The molecular profile is now equally important. A patient with stage 4 lung adenocarcinoma and an EGFR mutation receiving osimertinib can live many years. A patient with the same stage but without a targetable mutation has a different trajectory. This is why thorough molecular testing at diagnosis is not optional.
Next Steps
For any newly diagnosed lung cancer patient, the most important next steps are to obtain complete imaging and pathology, to confirm full molecular testing, and to be seen by a multidisciplinary team at a high volume center. Top Chinese centers for lung cancer include Shanghai Chest Hospital, Cancer Hospital Chinese Academy of Medical Sciences in Beijing, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center in Guangzhou, and West China Hospital in Chengdu. Each runs weekly thoracic tumor boards and treats large volumes of international patients.
Smoking cessation, pulmonary rehabilitation, vaccination, and nutrition all matter alongside cancer directed therapy. The combination often determines whether a patient can complete the planned treatment.
Frequently Asked Questions
Is lung cancer always caused by smoking?
No. Smoking is the largest single cause, but lung cancer also occurs in non smokers. Non smoker lung cancer is more often adenocarcinoma and more often driven by specific molecular alterations that respond well to targeted therapy.
How long does it take to get a complete workup in China?
At a high volume center with pre arrival document review, the full workup including imaging, biopsy, and molecular testing is typically complete in 5 to 10 working days. Treatment can start shortly after the tumor board reviews the case.
Can I get a second opinion remotely before traveling?
Yes. Many top Chinese centers offer remote review of prior imaging and pathology before the patient travels. This helps confirm whether traveling is worthwhile and what tests will be needed on arrival.
What about clinical trials?
Top Chinese centers run a growing number of clinical trials for lung cancer, including phase 1 trials of novel targeted agents and immune therapies. International self-pay patients are sometimes eligible. SinoCareLink can help identify trials that match a specific molecular profile.
Need Help Booking?
SinoCareLink can pre-book your thoracic oncology consultation, translate reports into English, and arrange airport pickup. Contact us for a free consultation.